Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round attracted prominent leaders in AI and ...

Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr.

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary ...

How much does your professional bio matter? Turns out, quite a bit. When people secure legal services, they are investing in an individual: in their expertise, knowledge, and ability to solve their ...